Introduction
Viral diseases in the clinical setting are extensively investigated nowadays, not only because of emerging diseases, such as severe acute respiratory syndrome or avian flu, but also because of the availability of modern diagnostic tests that rapidly detect known viruses and permit the identification of new viruses. Viruses are now also considered as potentially responsible for nosocomial infections, especially in intensive care unit (ICU) patients [1, 2] . Indeed, as the bacteriological causal agent of nosocomial pneumonia remains unknown in many cases, some authors suggested that viruses could be responsible for nosocomial infections, mainly pneumonia [2] [3] [4] [5] [6] [7] . The imputability and the incidence of viruses as causes of ventilator-associated pneumonia (VAP) are difficult to establish in adults because these agents are not searched for in many cases and because they are difficult to diagnose. The incidence of viral hospital-acquired pneumonia is therefore probably underestimated. Currently, cytomegalovirus and herpes simplex virus are the two most detected causal agents of VAP. Cytomegalovirus can be responsible for VAP in non-immunosuppressed ventilated patients [1, 2, [8] [9] [10] [11] [12] . Papazian et al. [5] performed 86 biopsies or autopsies in non-immunocompromised mechanically ventilated medical and surgical patients who presented with acute respiratory failure and/or symp-toms suggestive of VAP. Cytomegalovirus pneumonia was diagnosed in 25 patients. Recent reports suggest that Mimivirus could be an agent of pneumonia in critically ill mechanically ventilated patients. Mimivirus is the largest virus known to date. Its genome sequence encodes more than 900 proteins. Many of these proteins have functions that have never been encountered in a virus. While other amoeba-associated microorganisms from environmental sources, such as Legionella pneumophila , are known to cause acute pneumonia, the role of Mimivirus as a putative pneumonia agent remains a matter of debate.
Mimivirus Description
Mimivirus is a giant DNA virus that was isolated in 1992. An outbreak of community-acquired pneumonia in Bradford (England) triggered an investigation for Legionella -like bacteria in the water of a nearby cooling tower. Instead of the expected Gram-negative bacilluslike Legionella , a microorganism that looked like a small Gram-positive coccus was found that was able to propagate within the amoeba Acanthamoeba polyphaga . The investigator named the new intracellular parasite 'Bradford coccus' [13] . However, all attempts of culture on agar plates failed, as did molecular identification using universal 16S rDNA bacterial primers. Ten years later, the sample containing the microorganism was brought to Didier Raoult's lab at the University of Marseille, France. The ultrastructure of Bradford coccus was examined by electronic microscopy. 'Unbacterial' bodies within infected amoebae were observed. These bodies consisted of regular icosahedral forms, much like those observed in Iridoviruses [14] . This organism contained a large double-stranded DNA chromosome and possessed an eclipse-phase replication typical of viruses. Hence, this agent was considered as a virus. It was named Acanthamoeba polyphaga mimivirus for its amoeba host and bacteria-mimicking characteristics ( fig. 1 ) . Then, the analysis of several gene sequences exhibited a clear phylogenetic affinity with nucleocytoplasmic large DNA virus (NCLDV), a group of viruses including Poxviridae, Iridoviridae, Phycodnaviridae and Asfarviridae. Mimivirus is now classified as the first and prototype member species of Mimiviridae, a new family within the NCLDV.
Mimivirus Biology
Mimivirus is a double-stranded DNA virus [14] . Its size is similar to that of small bacteria such as Mycoplasma species, Rickettsia species, Coxiella burnetii, or Tropheryma whipplei [13] . Mimivirus does not pass through a 0.22-m-pore filter, the usual experimental procedure to separate bacterial cells from viruses. A computer-generated 3D image was constructed from series of cryoelectronic microscopy images [15] . The Mimivirus capsid has a diameter of about 0.5 m and is covered by 0.125-m-long, closely packed fibers. The total diameter of a free particle is thus roughly 0.75 m, consistent with its being visible under light microscope. Mimivirus possesses a genome size of 1.2 Mb. Its genome is larger than those of several bacteria [16] and represents the largest coding capacity for a virus. At present, 911 protein-encoding genes have been identified. Only 298 proteins have predicted functions. Mimivirus is a virus infecting the common amoeba A. polyphaga , a free-living amoeba that possesses major phagocytic activity [13] . Recently, Ghigo et al. [17] demonstrated that Mimivirus particles were internalized by macrophages through phagocytosis but not by nonprofessional phagocytic cells, leading to a productive cycle of virus replication. Mimivirus is the first virus able to penetrate professional phagocytes by this mechanism, classically used by bacteria or parasites.
In the latter study, Mimivirus appears to be a pathogen for macrophages [17] . Finally, the authors hypothesized that Mimivirus replicates within alveolar macrophages, potentially leading to human and murine pneumonia [17] .
Diagnosis of Mimivirus Infections
Because antibodies against several amoeba-associated bacteria were found in patients with community-or hospital-acquired pneumonia [18, 19] , La Scola et al. [20] tested antibodies to Mimivirus by using a microimmunofluorescence assay on serum samples from these patients. For the microimmunofluorescence assay, Mimivirus was grown in A. polyphaga, purified, and used as antigen. All methods of diagnosis used in humans are detailed in table 1 [20] [21] [22] [23] [24] [25] .
Mimivirus DNA was found in a bronchoalveolar lavage specimen by a nested PCR assay in only one patient [20] . No serum sample was available from this patient [20] .
Experimental Pneumonia with Mimivirus
To establish a possible role of Mimivirus as a pneumonia agent, Khan et al. [26] inoculated 12 mice with Mimivirus via intracardiac route. The intranasal route for inoculation permits cultivation of Mimivirus from lung tissues but lacks reproducibility [unpubl. data]. Histopathological evidence of acute pneumonia was reported in 9 of 12 (75%) animals. Pneumonia was characterized by the presence of thickened alveolar walls with cellular infiltrates comprising mononuclear leukocytes, macrophages and lymphocytes, and diffuse alveolar damage with the formation of hyaline membrane and erythrocytes in the alveolar lumen. In all infected mice, Mimivirus was cultured from lung tissue, or Mimivirus antigens were detected by indirect immunofluorescence assay on lung tissue. These results strongly suggest that Mimivirus is able to cause pneumonia under experimental conditions.
Pneumonia and Mimivirus in the Clinical Setting
The first large study suggesting that Mimivirus could be an agent of pneumonia was carried out in Canada and in France [20] . Serum samples from 887 Canadian people were tested. There were 376 Canadian patients with community-acquired pneumonia (121 ambulatory and 255 hospitalized) and 511 healthy control subjects. Among the 511 healthy Canadian controls, only 12 (2.3%) exhibited a substantial titer of antibodies to Mimivirus, whereas 36 (9.66%) of the 376 patients with community-acquired pneumonia were positive (p ! 0.01). The rehospitalization rate after discharge was higher in the group of patients with community-acquired pneumonia associated with Mimivirus antibodies than in controls. This higher rehospitalization rate is likely explained by the lack efficacy of antimicrobial agents against viruses. In the same study, Mimivirus was found in bronchoalveolar lavage specimens from 1 of 32 patients with ICU-acquired pneumonia and in none of the specimens from 21 intubated control patients in ICU who did not have pneumonia. Mimivirus DNA was detected in a bronchoalveolar lavage specimen from a 60-year-old comatose patient who had two episodes of hospital-acquired pneumonia during stays in the ICU. In another study on ICU patients [21] , serum samples were collected for 62 episodes of community-acquired pneumonia, 120 episodes of nosocomial pneumonia, and 28 episodes of community-acquired pneumonia complicated by a nosocomial infection. A fourfold increase in antibody titer between acute and convalescent-phase serum samples or a seroconversion from 0 to 1 1: 100 indicated strong evidence of Mimivirus infection. A low level of evidence for Mimivirus infection included a stable antibody titer of 6 1: 400. A positive serology for Mimivirus was found in 15 cases (10 ventilator-associated pneumonia and two communityacquired pneumonia). Eight of these 15 cases showed strong evidence of Mimivirus infection (fourfold increase in antibody titer between acute and convalescent-phase serum samples or a seroconversion from 0 to 1 1: 100) [21] . More recently, Vincent et al. [25] performed a matchedcohort study on 55 patients with a positive serology for Mimivirus matched to 55 seronegative patients. Patients with a positive serology for Mimivirus showed median excesses in durations of mechanical ventilation of 7 days (-3.5 to 24 days) and of ICU stay of 10 days (-11 to 22 days). This longer duration of mechanical ventilation was not related to a difference in the incidence of bacterial VAP because the patients were matched according to the presence or absence of such an infection during their ICU stay. There was no alternative explanation for the longer duration of mechanical ventilation and ICU stay in the group of patients with a positive serology for Mimivirus. Indeed, cases and controls did not differ in rate of shock, acute respiratory distress syndrome, further nosocomial infection, or acute renal failure. All these results strongly suggest that Mimivirus is a human pathogen, especially in severely ill patients. However, to the best of our knowledge, histological signs of Mimivirus pneumonia have never been described in humans.
In contrast, studies using PCR assays found no signs that Mimivirus could be pathogenic in humans. Dare et al. [22] screened 496 respiratory specimens from nine pneumonia patient populations for Mimivirus by two recently developed real-time PCR assays. These populations consisted of patients with community-or hospitalacquired pneumonia and bone marrow or lung transplant recipients with pneumonia. These PCR were performed mainly on nasal and nasopharyngeal swabs. No positive results were obtained for Mimivirus DNA by either assay [22] . However, most of the tested specimens were from the upper respiratory tract, whereas the only Mimivirus sample reported to be PCR-positive was from a lower respiratory bronchoalveolar lavage specimen [20] . Moreover, the patient populations sampled may not represent those at highest risk for Mimivirus infection.
An Austrian study [23] investigated a total of 214 nasopharyngeal aspirate samples from children admitted to hospital because of bronchiolitis, bronchitis or pneumonia. The authors used the same PCR protocol for detection of Mimiviridae in respiratory samples as the one used by La Scola et al. [20] . To avoid specimen contamination during detection of such a rare pathogen, a 'suicide PCR' protocol was used, which was described previously for detection of Yersinia pestis , the agent of medieval black death [27] . In the suicide PCR, primers are used only once, and there are no positive controls introduced into the laboratory. A negative test result is followed by a new test using other primers; a positive result is followed by sequencing. Although this procedure restricts the sensitivity of detection of Mimivirus to a certain extent, it improves specificity by avoiding cross-contamination [20] . Mimivirus, however, was not detected in any of the respiratory samples from the Austrian children [23] .
To explain these controversial results, the following explanations are possible. First, Mimivirus and Mamavirus were recently identified as the sole members of the Mimiviridae family. It was likely that lack of amplification of a virus close but different from Mimivirus could be due to a polymorphism in the area chosen for amplification. This hypothesis is supported by the recent discovery of many Mimivirus-related viruses [28] . Although DNA polymerase is among the most conserved genes in the NCLDV family, it was not possible to design universal primers to amplify this gene in the 19 new giant viruses isolated in the latter study [28] , even with viruses that appear phylogenetically very close. In fact, although sequence conservation is relatively high at the protein level, the nucleotide sequences vary widely [28] . Also, Mimivirus was shown to contain many proteins, of which up to 23 lead to production of antibodies [24] . It is then possible that Mimivirus-related virus proteins cross-react with those of Mimivirus even if molecular detection of Mimivirus is negative. Moreover, because Mimivirus is an amoeba-associated pathogen, exposures to Mimivirus most likely occur from environmental sources like contaminated hospital water supplies [22] , which is the case in ICU patients. The high rate of seroconversion in patients with pneumonia in some studies [20, 21, 25] suggests that community-acquired pneumonia and hospitalacquired pneumonia patients may have had contact with Mimivirus or a cross-reacting agent. Indeed, in a recent paper, Pelletier et al. [29] reported that among 38 tularemia sera tested, 20 presented cross-reactivity to Mimivirus. The latter study emphasizes the pitfalls of serological diagnosis of respiratory pathogens. Although testing of specific epitopes in immunoenzymatic assays is supposed to improve specificity as compared with wholeagent testing such as microimmunofluorescence, the previous results show that this does not guarantee a lack of cross-reactions with other pathogens responsible for the same clinical picture. The report of a case of pneumonia in a technician also suggests Mimivirus has a real pathogenic role [24] . This technician was a 38-year-old man who was tested yearly for antibodies against microorganisms that he manipulated in Western blot assays. He had never previously exhibited antibodies to Mimivirus. About 15 days after the onset of a dry cough, he presented with fever, chills, weakness and productive cough. Treatment with amoxicillin-clavulanate, 2 g/day for 8 days, was initiated. On day 23, he returned for follow-up evaluation because his symptoms had not improved. Chest X-ray tests showed bilateral basilar infiltrates suggesting viral pneumonia. Results of serologic studies for usual pneumonia-causing agents were negative, but Mimivirus seroconversion from ! 1: 50 to 1: 3,200 was documented. The patient slowly recovered. The technician was exposed to the virus, developed pneumonia, and exhibited seroconversion to 23 specific proteins (four of which were encoded by very specific genes without homologues in the National Institutes of Health GenBank).
Conclusions
Viruses are potential agents of pneumonia in both immunocompromised and non-immunocompromised patients. The precise mechanism leading to pneumonia remains unclear. The viruses seem to be associated with poorer outcome in ICU patients. Antibodies to Mimivirus have been found in patients with community-or hospital-acquired pneumonia. Unfortunately, Mimivirus DNA has been amplified from bronchoalveolar lavage in only one patient with nosocomial pneumonia. This discrepancy might be explained by the high polymorphism of nucleotide sequences of giant virus genes. Further studies are needed to confirm the pathogenicity of Mimivirus in humans and to determine the patient populations that are more likely to develop a pneumonia related to Mimivirus.
